Exagen (XGN) Equity Average (2018 - 2025)
Exagen (XGN) has disclosed Equity Average for 8 consecutive years, with $17.8 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Average rose 58.81% year-over-year to $17.8 million, compared with a TTM value of $17.8 million through Dec 2025, up 58.81%, and an annual FY2025 reading of $13.5 million, down 16.27% over the prior year.
- Equity Average was $17.8 million for Q4 2025 at Exagen, down from $19.6 million in the prior quarter.
- Across five years, Equity Average topped out at $98.9 million in Q2 2021 and bottomed at $8.0 million in Q1 2025.
- Average Equity Average over 5 years is $43.2 million, with a median of $31.8 million recorded in 2023.
- The sharpest move saw Equity Average soared 103.61% in 2021, then crashed 62.65% in 2025.
- Year by year, Equity Average stood at $87.9 million in 2021, then plummeted by 43.87% to $49.3 million in 2022, then plummeted by 49.11% to $25.1 million in 2023, then tumbled by 55.36% to $11.2 million in 2024, then surged by 58.81% to $17.8 million in 2025.
- Business Quant data shows Equity Average for XGN at $17.8 million in Q4 2025, $19.6 million in Q3 2025, and $13.7 million in Q2 2025.